01/27/23 4:05 PMNasdaq : PGEN offeringPrecigen Announces Closing of Public Offering of Common StockPrecigen, Inc. announced today the closing of its previously announced underwritten public offering of common stock. Precigen sold 42,857,143 shares of its common stock at a public offering price of $1.75 per share. Gross proceeds to Precigen from the offering were approximately $75.0 million before deducting the underwriting discount and other...RHEA-AIneutral
01/24/23 10:40 PMNasdaq : PGEN offeringPrecigen Announces Pricing of $75.0 Million Public Offering of Common StockPrecigen, Inc. today announced the pricing of an underwritten public offering of 42,857,143 shares of its common stock at a public offering price of $1.75 per share. Precigen has also granted the underwriters a 30- day option to purchase up to an additional 6,428,571 shares of its common stock. Precigen intends to use the net proceeds from the offering to fund...RHEA-AIneutral
01/24/23 4:05 PMNasdaq : PGEN offeringPrecigen Announces Proposed $75.0 Million Public Offering of Common StockPrecigen, Inc. (Nasdaq: PGEN) today announced it has commenced an underwritten public offering of $75.0 million of its common stock. In addition, Precigen intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 millionRHEA-AIneutral
01/24/23 4:01 PMNasdaq : PGEN clinical trialPrecigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory PapillomatosisPrecigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announces positive Phase 1 dose escalation and expansion cohort data as of the January 12, 2023 cutoff for the investigational, potential first-in-class PRGN-2012 off-the-shelf AdenoVerse™...RHEA-AIneutral
01/11/23 6:45 PMNasdaq : PGEN Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference– Company achieved significant progress for its clinical pipeline in 2022 – – Precigen to host R&D Day virtual event on January 24, 2023, at 4:30 PM ET to share safety and efficacy data from the Phase 1 dose escalation and expansion cohorts of PRGN-2012 AdenoVerse™ immunotherapy in recurrentRHEA-AIvery positive
01/04/23 4:05 PMNasdaq : PGEN conferencesclinical trialPrecigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse™ Immunotherapy in Recurrent Respiratory PapillomatosisPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will host an investigator-led R&D event on January 24,RHEA-AIpositive
12/19/22 4:05 PMNasdaq : PGEN conferencesPrecigen to Present at the 41st Annual J.P. Morgan Healthcare ConferencePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present aRHEA-AIneutral
12/12/22 7:01 PMNasdaq : PGEN clinical trialPrecigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients– Single infusion of UltraCAR-T cells with or without lymphodepletion demonstrated robust expansion and persistence in blood and bone marrow –– PRGN-3006 infusion with lymphodepletion resulted in a decrease in bone marrow blasts in 60% of heavily pre-treated patients –– Single infusion ofRHEA-AIneutral
11/09/22 4:05 PMNasdaq : PGEN earningsPrecigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs– Company will host virtual R&D event in early January 2023, timed to coincide with the 41 st Annual JP Morgan Healthcare Conference , to showcase complete clinical trial data from Phase 1 dose escalation and expansion cohorts of PRGN-2012 AdenoVerse ™ Immunotherapy in recurrent respiratoryRHEA-AIneutral
11/02/22 4:30 PMNasdaq : PGEN earningsPrecigen to Announce Third Quarter 2022 Financial Results on November 9thPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release third quarter 2022 financial results after theRHEA-AIneutral